Core Viewpoint - The medical device industry experienced a slight decline of 0.02% on July 23, with a total capital inflow of 23.87 million [1] Group 1: Market Performance - A total of 49 stocks in the sector rose, while 71 stocks fell [1] - The top ten decliners included: - JinHao Medical (-6.2%) - WeiSi Medical (-6.18%) - BeiYiKang (-5.91%) - Rejing Biology (-5.1%) - AiPeng Medical (-3.78%) - DiRui Medical (-3.55%) - YingKe Medical (-2.78%) - AiWei Technology (-2.58%) - YiRui Technology (-2.46%) - KangTuo Medical (-2.35%) [1] Group 2: Capital Flow - The net capital outflow for the top decliners included: - JinHao Medical: -15.52 million - WeiSi Medical: -13.50 million - BeiYiKang: -9.36 million - Rejing Biology: -14.75 million - AiPeng Medical: -15.57 million [1] Group 3: Top Gainers - The top gainers in the sector included: - OuPuKangShi (14.13%) - TouJing Life (5.7%) - KangZhong Medical (5.07%) - TianYi Medical (4.97%) - AoTai Biology (3.52%) [1]

Group 1 - The core viewpoint of the articles highlights the performance and valuation of the company,透景生命, within the medical device industry, noting its current stock price and market capitalization [1][2] - As of July 16, the company's closing stock price was 16.18 yuan, reflecting a 3.45% increase, with a rolling PE ratio of 66.60, marking a new low in 141 days, and a total market value of 2.63 billion yuan [1] - The average PE ratio for the medical device industry is 51.87, with a median of 37.48, positioning 透景生命 at 93rd in industry rankings [1][2] Group 2 - The company reported a revenue of 74.89 million yuan for Q1 2025, representing a year-on-year decrease of 19.53%, while net profit was 471,700 yuan, showing a significant increase of 110.51%, with a gross margin of 63.66% [1] - As of March 31, 2025, the number of shareholders for 透景生命 was 17,040, a decrease of 590 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1]

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Tongjing Life, which closed at 15.24 yuan with a PE ratio of 62.73, marking a new low in 75 days, and a total market capitalization of 2.477 billion yuan [1] - The average PE ratio for the medical device industry is 51.36, with a median of 37.22, placing Tongjing Life at the 92nd position in the industry ranking [1] - As of March 31, 2025, the number of shareholders for Tongjing Life is 17,040, a decrease of 590 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] Group 2 - Tongjing Life focuses on the research, production, and sales of in vitro diagnostic products under its own brand, with major products including diagnostic reagents, instruments, and service income [1] - The company actively participates in various health-themed public welfare activities and has received multiple awards for its social responsibility efforts, including the "Social Public Welfare Award" from the China Cancer Foundation [1] - In the latest quarterly report for Q1 2025, Tongjing Life reported an operating revenue of 74.8931 million yuan, a year-on-year decrease of 19.53%, and a net profit of 471,700 yuan, a year-on-year increase of 110.51%, with a gross profit margin of 63.66% [1]

证券代码：300642 证券简称：透景生命 公告编号：2025-046 一、回购股份的进展情况 截至 2025 年 6 月 30 日，公司通过股票回购专用账户以集中竞价交易方式累 计回购股份 0 股，占公司当前总股本的 0%，支付的总金额为人民币 0 元（不含 交易费用）。 二、其他说明 公司后续将根据市场情况在本次回购股份方案规定的回购期限内择机做出 回购决策并予以实施，并将在回购期间根据相关法律、法规和规范性文件的规定 及时履行信息披露义务，敬请广大投资者注意投资风险。 上海透景生命科技股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 上海透景生命科技股份有限公司（以下简称"公司"）于 2025 年 4 月 8 日 召开第四届董事会第八次会议，审议通过了《关于以集中竞价交易方式回购公司 股份的议案》。本次回购的股份用于股权激励或员工持股计划，用于回购股份的 资金总额不低于人民币 2,000 万元（含）且不超过人民币 4,000 万元（含），回 购股份价格不超过 16.00 元/股（含），实施期限为自公司董事会审议通过 ...

| 名称 | 上海透景生命科技股份有限公司 | | --- | --- | | 统一社会信用代码 | 91310000756110429R | | 类型 | 股份有限公司(上市、自然人投资或控股) | | 住所 | 上海市浦东新区汇庆路 412 号 | | 法定代表人 | 姚见儿 | | 注册资本 | 人民币 16255.6041 万元整 | | 成立日期 | 2003 年 11 月 06 日 | | 经营范围 | 一般项目：第一类医疗器械生产（限分支机构经营）；第二类医疗 | | | 器械销售；第一类医疗器械销售；工程和技术研究和试验发展；医 | | | 学研究和试验发展；技术服务、技术开发、技术咨询、技术交流、 | | | 技术转让、技术推广；医疗设备租赁；非居住房地产租赁；货物进 | | | 出口；技术进出口。（除依法须经批准的项目外，凭营业执照依法 | | | 自主开展经营活动） | | | 许可项目：第三类医疗器械生产；第二类医疗器械生产；第三类医 | | | 疗器械经营；医疗器械互联网信息服务。（依法须经批准的项目， | | | 经相关部门批准后方可开展经营活动，具体经营项目以相关部门批 | 证券 ...

证券代码：300642 证券简称：透景生命 公告编号：2025-044 上海透景生命科技股份有限公司 关于取得发明专利证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 上海透景生命科技股份有限公司（以下简称"透景生命"或"公司"）及全 资子公司上海透景诊断科技有限公司（以下简称"透景诊断"或"全资子公司"） 于近日收到中华人民共和国国家知识产权局颁发的 2 项发明专利证书，具体情况 如下： | 序号 | 专利名称 | 专利号 | 专利权人 | 专利类型 | 申请日期 | 有效期 | 证书号 | | --- | --- | --- | --- | --- | --- | --- | --- | | 1 | 一种高均一性单价链霉亲 | ZL 2019 1 | 透景生命； | 发明专利 | 2019 年 07 | 20 年 | 第 7981836 号 | | | 和素四聚体的应用 | 0684915.1 | 透景诊断 | | 月 26 日 | | | | 2 | 一种由高均一性单价链霉 亲和素四聚体在免疫化学 | ZL 2020 1 | 透景生命； | | ...

证券代码：300642 证券简称：透景生命 公告编号：2025-043 关于全资子公司取得医疗器械注册证的公告 上海透景生命科技股份有限公司（以下简称"公司"）的全资子公司江西透 景生命科技有限公司（以下简称"子公司"或"江西透景"）于近日取得江西省 药品监督管理局颁发的 2 项医疗器械注册证，具体情况如下： | 产品名称 | 注册证编号 | 注册证有效期 | 注册分类 | 预期用途 | | --- | --- | --- | --- | --- | | 纤维蛋白（原）降 | | 2025 年 06 月 23 | | 用于体外定量检测人血浆中纤维蛋 | | 解产物测定试剂 | 赣械注准 | 日至 2030 年 06 | 第二类体外 | 白（原）降解产物（FDP）的含量。 | | 盒（化学发光免疫 | 20252400097 | 月 22 日 | 诊断试剂 | 临床上用于原发性和继发性纤维蛋 | | 分析法） | | | | 白溶解功能亢进辅助诊断。 | | 纤溶酶-α2纤溶酶 | | | | 用于体外定量检测人血浆中纤溶酶 | | 抑制剂复合物测 | 赣械注准 | 2025 年 06 月 23 日至 2030 ...

证券代码：300642 证券简称：透景生命 公告编号：2025-042 上海透景生命科技股份有限公司 关于部分股票期权注销完成和部分限制性股票回购注销完成的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、上海透景生命科技股份有限公司（以下简称"公司"或"透景生命"） 本次注销的股票期权涉及 54 人，注销的股票期权数量共计 1,661,400 份。其中， 2020 年股票期权与限制性股票激励计划股票期权（透景 JLC1）594,000 份，2023 年股票期权与限制性股票激励计划股票期权（透景 JLC2）1,067,400 份。 2、公司本次回购注销的限制性股票涉及 54 人，回购注销的股份数量共计 465,900 股，占回购注销前公司总股本 163,021,941 股的 0.2858%。其中，2020 年股票期权与限制性股票激励计划限制性股票的回购价格为 14.03 元/股，2023 年股票期权与限制性股票激励计划限制性股票的回购价格为 10.65 元/股，本次 限制性股票回购总金额为 5,415,093 元。 3、截至本公告披露日，公 ...

Core Viewpoint - The company and its wholly-owned subsidiary, Shanghai Toukang Diagnostic Technology Co., Ltd., have recently received acceptance for their medical device registration applications from the Shanghai Municipal Drug Administration, which includes seven products across various diagnostic fields [1] Group 1: Product Registration - The accepted products include carcinoembryonic antigen, cytokeratin 19 fragment, neuron-specific enolase, squamous cell carcinoma antigen, gastrin-releasing peptide precursor assay kit (flow fluorescence method), 25-hydroxyvitamin D assay kit (chemiluminescent immunoassay), anti-double-stranded DNA antibody, anti-C1q antibody, anti-M2-3E antibody, anti-nucleosome antibody, and anti-phospholipid syndrome IgA antibody assay kit (flow fluorescence method) [1] - These products cover tumor detection, metabolic detection, and autoimmune detection, which will help enrich the company's product line, meet market demand, and enhance market competitiveness [1] Group 2: Approval Process - The current stage of the approval process is the acceptance of the registration application, with subsequent steps including technical review, administrative approval, and issuance of the license [1] - The acceptance of these product registration applications will not have an impact on the company's or Toukang Diagnostic's recent performance [1]

证券代码：300642 证券简称：透景生命 公告编号：2025-041 上海透景生命科技股份有限公司 关于申报医疗器械注册获得受理的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 上海透景生命科技股份有限公司（以下简称"公司"或"透景生命"）及全 资子公司上海透景诊断科技有限公司（以下简称"透景诊断"或"全资子公司"） 申报的医疗器械注册申请于近期获得了上海市药品监督管理局的受理，具体情况 如下： | 序号 | 产品名称 | 注册分类 | 申请人 | 预期用途 | | --- | --- | --- | --- | --- | | | 癌胚抗原、细胞角蛋白 | | | 本试剂盒用于定量检测人血清中 | | | 19 片段、神经元特异性 | | | CEA、CYFRA21-1、NSE、SCC 和 ProGRP | | | 烯醇化酶、鳞状上皮细 | 第二类体 | 透景 | 的浓度。用于对肺癌患者的治疗监 | | 1 | | 外诊断试 | | | | | 胞癌抗原、胃泌素释放 | 剂 | 生命 | 测，不能作为恶性肿瘤早期诊断或确 | | | 肽前体测定试剂盒 ...